Hitoshi Kohsaka


Affiliation: Tokyo Medical and Dental University
Country: Japan


  1. request reprint
    Kohsaka H, Nasu K, Matsushita S, Miyasaka N. Complete cDNA coding sequence of the HLA-DRB1*1405 allele. DNA Seq. 2002;13:359-61 pubmed
    ..Functional analyses would discern if these allelic differences in the cytoplasmic domain are of functional significance. ..
  2. Okiyama N, Hasegawa H, Oida T, Hirata S, Yokozeki H, Fujimoto M, et al. Experimental myositis inducible with transfer of dendritic cells presenting a skeletal muscle C protein-derived CD8 epitope peptide. Int Immunol. 2015;27:327-32 pubmed publisher
    ..Because this myositis model is mediated by CD8 T cells independently of CD4 T cells, it should be a useful tool to investigate pathology of polymyositis and develop therapies targeting CD8 T cells. ..
  3. Umezawa N, Kawahata K, Mizoguchi F, Kimura N, Yoshihashi Nakazato Y, Miyasaka N, et al. Interleukin-23 as a therapeutic target for inflammatory myopathy. Sci Rep. 2018;8:5498 pubmed publisher
    ..Our findings suggest that IL-23 should mediate positive feedback loop from the muscle damage to the T cell activation and be a promising therapeutic target for autoimmune myositis. ..
  4. Tagawa Y, Saito T, Takada K, Kawahata K, Kohsaka H. Successful treatment of severe refractory lupus hepatitis with mycophenolate mofetil. Lupus. 2016;25:543-6 pubmed publisher
    ..Mycophenolate mofetil might be an effective therapeutic option for refractory lupus hepatitis. ..
  5. request reprint
    Hasegawa H, Kawahata K, Mizoguchi F, Okiyama N, Miyasaka N, Kohsaka H. Direct suppression of autoaggressive CD8+ T cells with CD80/86 blockade in CD8+ T cell-mediated polymyositis models of mice. Clin Exp Rheumatol. 2017;35:593-597 pubmed
    ..CTLA4-Ig should be a potential therapeutic agent of PM and other CD8+T cell-mediated diseases by suppressing both autoantigen-specific CD4+ and CD8+ T cells. ..
  6. Matsuo Y, Mizoguchi F, Saito T, Kawahata K, Ueha S, Matsushima K, et al. Local fibroblast proliferation but not influx is responsible for synovial hyperplasia in a murine model of rheumatoid arthritis. Biochem Biophys Res Commun. 2016;470:504-509 pubmed publisher
    ..Suppression of proliferation of the local synovial fibroblasts should be a promising treatment for RA. ..
  7. Yokoyama W, Kohsaka H, Kaneko K, Walters M, Takayasu A, Fukuda S, et al. Abrogation of CC chemokine receptor 9 ameliorates collagen-induced arthritis of mice. Arthritis Res Ther. 2014;16:445 pubmed publisher
    ..The interaction between CCL25 and CCR9 may play important roles in cell infiltration into the RA synovial tissues and inflammatory mediator production. Blocking CCL25 or CCR9 may represent a novel safe therapy for RA. ..
  8. Kim J, Choi J, Park S, Yang S, Park J, Shin K, et al. Therapeutic effect of anti-C-X-C motif chemokine 10 (CXCL10) antibody on C protein-induced myositis mouse. Arthritis Res Ther. 2014;16:R126 pubmed publisher
    ..625 vs. anti-RVG1 treatment group, 1.25, P?=?0.007). CXCL10/CXCR3 expression was increased in the inflammation of CIM model and its blockade suppressed inflammation in muscle. ..
  9. Mizoguchi F, Murakami Y, Saito T, Miyasaka N, Kohsaka H. miR-31 controls osteoclast formation and bone resorption by targeting RhoA. Arthritis Res Ther. 2013;15:R102 pubmed
    ..miR-31 controls cytoskeleton organization in osteoclasts for optimal bone resorption activity by regulating the expression of RhoA. ..

More Information


  1. Utsunomiya M, Dobashi H, Odani T, Saito K, Yokogawa N, Nagasaka K, et al. Optimal regimens of sulfamethoxazole-trimethoprim for chemoprophylaxis of Pneumocystis pneumonia in patients with systemic rheumatic diseases: results from a non-blinded, randomized controlled trial. Arthritis Res Ther. 2017;19:7 pubmed publisher
    ..The University Hospital Medical Information Network Clinical Trials Registry number is UMIN000007727 , registered 10 April 2012. ..